Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Abnova Corp. (4133:TWSE), powered by AI.
Abnova Corp. is currently trading at $20.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Abnova Corp. on Alpha Lenz.
View Abnova Corp.'s valuation metrics on Alpha Lenz.
“Abnova Corp.'s ROE is -0.1%. Explore profitability and growth together.”
Ask for details →Abnova Corp. is a leading biotechnology company that specializes in the development and production of antibodies and related biological reagents on a commercial scale. Its primary purpose is to supply a diverse range of bio-products for high-throughput research and diagnostic purposes, catering to the needs of scientists and medical researchers globally. With a focus on genomics and proteomics, Abnova leverages cutting-edge technology to produce comprehensive antibody libraries, genetic tools, and diagnostic kits. These products serve critical roles in the pharmaceutical, life sciences, and healthcare sectors by facilitating advanced research and the development of new therapeutic solutions. Headquartered in Taiwan, Abnova Corp. maintains a strong presence in the global biotech market, contributing significantly to advancements in biomarker discovery and personalized medicine. Its extensive pipeline of innovative products underscores its commitment to precision and quality, rendering it a valuable partner for research institutions and biotech companies alike.
“Abnova Corp.'s ROE is -0.1%. Explore profitability and growth together.”
Ask for details →Abnova Corp. (ticker: 4133) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 20.7 with a P/E ratio of -x and P/B of -x.
ROE is -0.09% and operating margin is 4.97%. Annual revenue is $351M.